Phase 1B- Open Label Dose-Ranging Study of Oral AFX-2 in Adults With Chronic Lymphocytic Leukemia

NCT01456182 · clinicaltrials.gov ↗

PHASE1

Phase

WITHDRAWN

Status

INDUSTRY

Sponsor class

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG: AFX-2
DRUG: AFX-2
DRUG: AFX-2
DRUG: AFX-2
DRUG: AFX-2

Sponsor

Afexa Life Sciences Inc